Table of Contents
Editorial
| COVID-19 vaccines: Equitable access, vaccine hesitancy and the dilemma of emergency use approvals | |
| Ames Dhai | 77 |
| Funding considerations for the use of experimental therapies for COVID-19 in the South African private sector | |
| Z Adam, R J Wiseman | 79 |
| COVID-19 millionaires must be held criminally accountable | |
| S Mahomed, G Loots, G Andrews | 81 |
Contents
| Contents | |
Articles
| Resource allocation during COVID-19: A focus on vulnerable populations | |
| C de V Castelyn, I M Viljoen, A Dhai, M S Pepper | 83 |
| ‘Please confirm your HIV-positive status by email to the following government address’: Protection of ‘vulnerable employees’ under COVID-19 | |
| D T Hagemeister, M R Mpeli, B E Shabangu | 91 |
| The HPCSA’s telemedicine guidance during COVID-19: A review | |
| B A Townsend, M Mars, R E Scott | 97 |
| Sharing human biobank samples and data in exchange for funding in South Africa in international collaborative health research – an ethicolegal analysis | |
| M Maseme, S Mahomed | 103 |
| Factors influencing truth-telling by healthcare providers to terminally ill cancer patients at Ocean Road Cancer Institute in Dar-es-Salaam, Tanzania | |
| R Athanas, F Gasto, S J Renatha | 108 |
| Prohibited substance regulation and compliance testing: A principalism approach | |
| J B Laurens, P A Carstens | 114 |
| Factors associated with refusal of hospital treatment at Odi District Hospital, Gauteng Province, South Africa | |
| D K Nzaumvila, L H Mabuza, M Mogotsi, T Bongongo, C N Saidiya | 119 |
| Multidisciplinary specialist treatment teams and abandonment of patients – who is responsible for what? | |
| D J McQuoid-Mason | 125 |
| Managed healthcare: Treatment protocols and fiduciary duties of funders | |
| D Masege, A Dhai | 129 |
CPD questions
| CPD questionnaire | |


.jpg)